In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.

A novel tool for rapidly identifying the genetic “fingerprints” of cancer cells may enable future surgeons to more accurately ...

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Con ...

"The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look forward ...

T UESDAY, Feb. 4, 2025 (HealthDay News) -- For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid ...

This combo regimen got the FDA's accelerated approval in December 2024, marking it as the first targeted therapy available for first-line treatment in BRAF V600E-mutant mCRC patients. The results?

A novel tool for rapidly identifying the genetic "fingerprints" of cancer cells may enable future surgeons to more accurately ...

In patients with metastatic colorectal cancer harboring a BRAF V600E mutation, the combo not only staved off disease progression but it also significantly extended patients’ lives compared with ...

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6. Dr. Marwan G. Fakih discussed the FDA approval of ...

Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal cancer.